5LINX(R) has been granted marketing rights for ChromaDex's recently launched patented NIAGEN(TM) Nicotinamide Riboside (NR) for use in dietary supplements exclusively in the network marketing sales channel in the United States, Canada and Philippines. Under the terms of the agreement, 5LINX(R) must purchase from ChromaDex $2.1 million of NIAGEN(TM) in 2014, and an aggregate of $46 million of NIAGEN(TM) from 2015 through 2017. NIAGEN(TM) is the first and only commercially available brand of NR, which is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3).

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. 5LINX(R) has also been granted marketing rights for ChromaDex's recently launched patented PURENERGY(TM) for use in dietary supplements, with select exclusively in the network marketing sales channel in the U.S., Canada and Philippines.

Under the exclusive network marketing channel agreement, 5LINX(R) must purchase from ChromaDex $520,000 of PURENERGY(TM) in 2014 and an aggregate of $14 million of PURENERGY(TM) from 2015 through 2017. ChromaDex's PURENERGY(TM) caffeine alternative is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure(R) pterostilbene, a potent anti-oxidant found in blueberries. The first human study of PURENERGY(TM) demonstrated PURENERGY(TM) delivers 30% more caffeine, stays in the blood stream longer, and is absorbed more slowly than ordinary caffeine.

With PURENERGY(TM), formulators of energy products may have the ability to reduce the total amount of caffeine in their products by as much as 50% without sacrificing consumers' expectations from such products.